Chemotherapy Foundations and Infusion Safety

Chemotherapy Foundations and Infusion Safety

Chemotherapy uses cytotoxic drugs to interrupt cancer-cell DNA replication, mitosis, or repair. Because these drugs also damage rapidly dividing normal tissue (marrow, mucosa, hair follicles), the registered nurse (RN) holds two ideas at once: antitumor intent and predictable harm. On the 2026 Oncology Nursing Certification Corporation (ONCC) blueprint, Treatment Modalities is 20% of the 165-question, 3-hour exam, and chemotherapy administration safety is one of its densest item clusters.

The RN does not select regimens or recalculate prescribed doses but verifies the ordered plan is complete, current, and clinically reasonable before the drug reaches the patient.

Cell-Cycle Classification Drives Toxicity Timing

Knowing whether an agent is cell-cycle-specific or nonspecific predicts nadir timing and teaching priorities.

Independent Double-Check Verification

The standard of care is a two-RN independent double-check of the signed order against protocol: patient identity with two identifiers, diagnosis, regimen name, drug sequence, dose, route, body surface area (BSA), cycle day, and supportive premedications. Recalculate BSA only per policy; never silently change a prescribed dose. Confirm consent, recent labs, and absolute neutrophil count (ANC). Vincristine is dispensed only in a minibag, never a syringe, to prevent accidental intrathecal administration, which is uniformly fatal.

Cumulative and Organ-Specific Toxicity

Some toxicities are dose-limited over a lifetime. Doxorubicin carries a cumulative ceiling near 450-550 mg/m2 because of irreversible cardiomyopathy; a baseline and serial left-ventricular ejection fraction (LVEF) is expected. Cisplatin is nephrotoxic and ototoxic, requiring vigorous hydration, magnesium repletion, and creatinine trending. Bleomycin risks pulmonary fibrosis at a lifetime ceiling near 400 units. The RN monitors trends and symptoms and escalates early rather than waiting for a single critical value.

USP <800> Hazardous Drug Handling

Chemotherapy preparation and administration follow USP General Chapter <800>: chemotherapy-rated gowns and double gloves, closed-system transfer devices (CSTDs), negative-pressure compounding, spill kits, and yellow chemotherapy waste. Spills are contained from the outside inward; staff don personal protective equipment (PPE) before approaching. These standards protect patients, caregivers, and the nurse from carcinogenic exposure.

Pre-Administration Lab and Readiness Checks

Before any cytotoxic dose, the RN confirms the absolute neutrophil count (ANC), platelet count, hemoglobin, creatinine and creatinine clearance, hepatic transaminases, bilirubin, and electrolytes, plus a pregnancy test when indicated. Common hold parameters in many protocols are an ANC below about 1,500/mcL or platelets below about 100,000/mcL, though exact thresholds are protocol-specific. The nurse also reviews the new-symptom history: a recent fall, worsening neuropathy, new antibiotics, an unreported fever, or missed premedications can all change readiness even when labs look acceptable.

When the patient's story does not match the written plan, the correct action is to pause the process and clarify, not to proceed and hope.

Worked Verification Example

Consider a patient ordered for doxorubicin and cyclophosphamide on day 1 of cycle 3. The RN and a second nurse independently confirm the BSA used (for example, 1.7 m2), recompute the expected milligram dose against the protocol, check that the cumulative anthracycline total remains well under the 450-550 mg/m2 ceiling, verify the antiemetic premedications are charted, and confirm a patent central line with blood return. If the cumulative doxorubicin had reached the ceiling, the RN would hold and notify the provider rather than administer.

This sequence, pause-verify-assess-communicate-document, is the high-reliability standard the exam rewards.

Predictable Toxicity Patterns

Myelosuppression is the most common dose-limiting toxicity. Neutrophils fall first because of their short lifespan, with the nadir typically 7-14 days after a dose and recovery by day 21-28 for many regimens, which is why ANC timing drives both cycle scheduling and fever-precaution teaching. Thrombocytopenia and anemia follow on their own timelines.

Gastrointestinal toxicity spans nausea, vomiting, diarrhea, constipation, mucositis, and anorexia; highly emetogenic regimens (cisplatin, high-dose cyclophosphamide) require a three-drug antiemetic plan combining a serotonin (5-HT3) antagonist, a neurokinin-1 (NK1) antagonist, and dexamethasone. Mucositis peaks around days 7-10 and worsens with neutropenia, so oral care and pain control are proactive, not reactive. Neurotoxicity (platinum ototoxicity, taxane and vinca neuropathy) and alopecia round out the predictable cluster, while methotrexate demands leucovorin rescue and urine alkalinization to prevent renal precipitation.

Knowing which toxicity is expected, and when, lets the nurse separate routine effects from the red flags that demand escalation, such as fever during the expected nadir.

Infusion Reaction Response

Reactions cluster in the first minutes and on rechallenge. Presentations include flushing, urticaria, chest tightness, dyspnea, wheezing, hypotension, back pain, rigors, or a sense of impending doom. The structured response is: stop the infusion, keep the line open with non-drug fluid, assess airway-breathing-circulation and vital signs, call for help or activate rapid response, position the patient, apply oxygen, and give emergency medications only under standing orders or provider direction. Document onset, symptoms, interventions, response, and whether rechallenge occurred.

The RN never reassures a patient that chest tightness during a first infusion is expected. After stabilization, verify discharge instructions match today's drugs and that the patient can repeat the urgent-call criteria using teach-back before leaving.